Emerging Technologies in Mitigating the Risks of Cardiac Toxicity From Breast Radiotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35688525.
- Also identified by DOI 10.1016/j.semradonc.2022.01.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Technical advances in radiation oncology may allow for greater reduction in the late toxicities associated with breast radiotherapy. In this review, we explore emerging technologies that show specific promise for the identification and reduction of radiation-induced cardiac toxicity namely, proton therapy and cardiac autosegmentation. First, we will examine the historical risks of cardiovascular morbidity and mortality in breast cancer, including trends in cardiac radiation exposure over time. Then, we will highlight the rationale for proton therapy, including the early dosimetric and clinical studies available to-date, to underscore proton therapy's unique potential for limiting cardiac radiation exposure and preserving cardiac function among patients with breast cancer, with consideration of modern cardiac dose constraints. Finally, we will focus on the development of cardiac contouring atlases and substructure auto-segmentation methods in order to demonstrate opportunities for integration of auto-segmentation into dosimetric planning and outcome prediction.
Medical subject headings
- Breast Neoplasms
- Proton Therapy
- Radiation Injuries